Literature DB >> 33813487

PRACTICAL MEANS OF PREOPERATIVE DIAGNOSTICS OF PRIMARY FALLOPIAN TUBE CANCER.

Dmytro H Sumtsov1, Igor Z Gladchuk2, Nataliia M Kashtalian2, Georgiy O Sumtsov1.   

Abstract

OBJECTIVE: The aim: To analyze contemporary practical means to improve diagnostics of primary fallopian tube cancer. PATIENTS AND METHODS: Materials and methods: Authors analyzed specifics of clinical signs and anamnesis in 152 PFTC patients. Diagnostic capacity of cytological analysis of pathologic vaginal discharge, X-ray contrast methods of examination, sonography, tumor markers, and computed tomography was studied. Own results of PFTC diagnostics using different methods and world practice using MRI, PET-CT and laparoscopy were discussed.
RESULTS:
Results: Using own observations authors conclude that clinical analysis and complex use of the listed methods allows to mainly determine high risk group patients and set correct preoperative diagnosis in 35% and preliminary diagnosis in 20% of PFTC patients.
CONCLUSION: Conclusions: Complex examination allows to recognize primary fallopian tube cancer on preoperative stage and to avoid inadequate surgical interventions in majority of PFTC patients.

Entities:  

Keywords:  complex examination; preoperative diagnostics ; primary fallopian tube cancer

Mesh:

Year:  2021        PMID: 33813487

Source DB:  PubMed          Journal:  Wiad Lek        ISSN: 0043-5147


  2 in total

1.  Primary Fallopian Tube Carcinoma: An Extremely Rare Gynecological Cancer Misdiagnosed Intraoperatively as Benign Ovarian Neoplasm: A Case Report.

Authors:  Efthymia Thanasa; Dimitra Stamouli; Ektoras-Evangelos Gerokostas; Konstantina Balafa; Nikoleta Koutalia; Ioannis Thanasas
Journal:  Clin Pract       Date:  2022-04-22

Review 2.  18-F fluorodeoxyglucose positron emission tomography/computed tomography findings of bilateral primary fallopian tube carcinoma and metastasis to the uterus: a case report and literature review.

Authors:  Na Dai; Shengming Deng; Yi Yang; Shibiao Sang
Journal:  J Int Med Res       Date:  2022-08       Impact factor: 1.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.